Semaglutide works by changing how your brain and gut regulate appetite. Wegovy delivers it as a once-weekly injection, with the dose building gradually over several months. It's also available as a tablet, which may follow a slightly different timeline.
Reduces appetite, helping you feel full and eat less
Best results come with lifestyle support, not medication alone
Builds over several weeks to avoid side effects
All content on this page has been medically reviewed by: Hassan Thwaini, Clinical Pharmacist and Copywriter, Master of Pharmacy (MPharm) on 16 February, 2026. GPhC Registration: 2221320View profile
If you're joining or are thinking of joining a weight loss programme, you might have been asking, "how long does Wegovy take to work?" In short, Wegovy is designed to work gradually. The dose is increased slowly over several months, allowing your body to adjust and helping to reduce side effects. This is why results build over time rather than happening all at once.1
Semaglutide, which is the active ingredient in Wegovy, is a medicine that mimics a natural hormone in your body called GLP-1 (glucagon-like peptide-1).1
GLP-1 is released by your gut after you eat and exerts a few different effects:2
It tells your brain that you’re full
It slows down how quickly food leaves your stomach
It reduces hunger signals and food cravings
Semaglutide is known as a GLP-1 receptor agonist. That simply means it acts like your natural GLP-1 hormone, but lasts much longer in the body. This is why Wegovy only needs to be injected once a week.1
It works in two main ways:
1. Reducing appetite signals
Semaglutide acts on appetite centres in the brain, including areas involved in hunger, reward, and motivation around food. Many people notice that they think about food less, feel satisfied with smaller portions, and find it easier to stop eating when they’re full.1
2. Slowing stomach emptying
Food leaves your stomach more slowly, so you stay full for longer after meals. This helps reduce snacking and overeating between meals.1
Wegovy and Ozempic contain the same active ingredient (semaglutide). The difference is the dose and the licence. Wegovy is approved specifically for weight loss at higher doses, while Ozempic is licensed for type 2 diabetes at lower doses.
Wegovy doesn’t start at a full dose. It begins at a very low dose and increases slowly over about five months. This process is called dose titration.
The reason for this is that starting low gives your body time to adapt and helps reduce side effects like nausea. You may notice appetite changes within the first few weeks, but most weight loss happens once you reach the higher maintenance doses.
If you’re searching for “Wegovy first month results”, you’re probably wondering whether it’s working yet. In month one, which is usually the lowest dose of Wegovy, the focus is on helping your body adjust safely. Many people start noticing early appetite changes, while more visible weight loss typically builds as the dose increases.
In the first month, you may notice:
Feeling full sooner during meals
Reduced “food noise” or fewer cravings
Naturally smaller portion sizes
Early weight loss, though usually gradual
The starting dose is designed to prepare your body. Stronger, more consistent weight loss often becomes clearer at higher maintenance doses, which can be seen below.
Results vary between individuals and depend on adherence, dose, and lifestyle support.
| Month | Dose (mg) | Primary goal | Expected weight loss (cumulative) |
|---|---|---|---|
| 1 | 0.25 | Let the body adjust and manage side effects | Early appetite changes |
| 2 | 0.5 | Continue dose increase | ~4% body weight³ |
| 3 | 1 | Stronger appetite control | ~6% body weight³ |
| 4 | 1.7 | Near therapeutic dose | ~8% body weight³ |
| 5 | 2.4 | Getting to max therapeutic effect | 10-17% body weight³ |
| 6+ | 7.2 | Enhanced dose - may be beneficial for some people | ~18.7-25% body weight by 68 weeks⁴ |
Many people notice appetite changes within the first few weeks, even at the starting 0.25mg dose. You might notice you get full faster or think about food less.3
However, meaningful weight loss usually accelerates at higher doses, especially:3
From 1.0mg upwards
Most clearly at 1.7mg and up
The early doses are mainly about preparing your body. They’re not designed to produce rapid weight loss. This is why progress can feel slow in the first couple of months.
Dose titration matters because:3,4
Starting too high increases side effects
Going slowly helps you stay on treatment
Long-term results are better when people can tolerate the medication
If weight loss feels slow at first, that’s expected. The strongest effects come once you reach the maintenance dose.
Side effects are most common when the dose increases. For most people, they‘re mild and temporary.
Common side effects include:5
Nausea
Vomiting
Diarrhoea or constipation
Abdominal discomfort or bloating
These usually settle as your body adapts, which is why Wegovy is increased slowly.
Eat smaller meals
Eat slowly and stop when full
Avoid very fatty or heavy meals early on
Stay hydrated
If side effects are severe or persistent, your clinician may slow down dose increases. You can read more in our full GLP-1 side effects blog.
Obesity is a chronic condition, influenced by biology, hormones, environment, and behaviour. Worldwide, rates of overweight and obesity have nearly tripled since the 1970s.6 Over a third of adults are now overweight, and more than 13% live with obesity. This comes with higher risks of heart disease, diabetes, stroke, and some cancers.7
Lifestyle changes like diet, exercise, and behaviour change are always the foundation. But many people struggle to maintain weight loss with lifestyle changes alone. This is where medication like Wegovy can help by making appetite easier to manage.
In clinical trials, semaglutide worked best when combined with:
Healthier eating patterns
Regular physical activity
Behavioural or coaching support
Wegovy doesn’t increase your metabolism. It mainly works by reducing energy intake, helping you eat less without feeling constantly hungry.
Long-term success comes from:
Staying consistent
Building habits you can maintain
Getting support when motivation dips
Starting dose
Second dose, often prescribed after 4-6 weeks
Possible maintenance doses
There are several weight loss injections available. They differ in how they work and how much weight loss they typically produce.
Wegovy contains semaglutide, a GLP-1 receptor agonist. Other options may:
Work on different appetite hormones
Affect insulin or fat metabolism differently
Be taken daily rather than weekly
In head-to-head and indirect comparisons, semaglutide has shown consistently strong average weight loss results among current weight loss medications.8 It's worth noting that Wegovy is currently the GLP-1 that also comes in tablet form.
If you want a deeper comparison, you can read our guide.
Wegovy works by changing how your brain and gut regulate hunger. It reduces appetite, helps you feel full for longer, and makes it easier to eat less without constant willpower. Results happen gradually because the dose increases slowly. Most people notice appetite changes within weeks, but the strongest weight loss usually starts at higher doses.
Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5–13
Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181–7.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949–63.
Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen. Org.uk. [accessed 19 Jan 2026] Available from: https://www.medicines.org.uk/emc/product/13799/smpc
Lustig RH, Collier D, Kassotis C, Roepke TA, Kim MJ, Blanc E, et al. Obesity I: Overview and molecular and biochemical mechanisms. Biochem Pharmacol. 2022;199(115012):115012.
Kitahara CM, Flint AJ, Berrington de Gonzalez A, Bernstein L, Brotzman M, MacInnis RJ, et al. Association between class III obesity (BMI of 40-59 kg/m2) and mortality: a pooled analysis of 20 prospective studies. PLoS Med. 2014;11(7):e1001673.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184(9):1056–64.
Medically reviewed:
